MLTX 1-WEEK DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

Core Insights - The lawsuit against MoonLake Immunotherapeutics, Inc. alleges that the company concealed material adverse facts regarding the clinical performance of its drug SLK, particularly in comparison to competitors like BIMZELX [2][3] - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these alleged misrepresentations [3] Legal Allegations - The lawsuit focuses on the alleged failure of MoonLake to disclose that SLK shares the same molecular targets as BIMZELX, which could mislead investors about its competitive positioning [3] - It is claimed that MoonLake misrepresented the efficacy of its Nanobody structure, suggesting it would provide superior clinical outcomes for treating hidradenitis suppurativa [3] - The legal focus includes whether investors are entitled to damages due to the alleged wrongful acts and omissions during the class period [3] Investor Actions - Investors who purchased MLTX shares between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact Hagens Berman for potential legal action [4] - The deadline for investors to move the court for appointment as lead plaintiff is December 15, 2025 [1][5] Firm Background - Hagens Berman has a strong track record, having secured over $2.9 billion in settlements for investors in similar cases [4][6] - The firm specializes in corporate accountability and represents various stakeholders, including investors and whistleblowers [6]